167 related articles for article (PubMed ID: 20473659)
1. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.
Gaedigk A; Isidoro-García M; Pearce RE; Sánchez S; García-Solaesa V; Lorenzo-Romo C; Gonzalez-Tejera G; Corey S
Eur J Clin Pharmacol; 2010 Sep; 66(9):859-64. PubMed ID: 20473659
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Gaedigk A; Bradford LD; Alander SW; Leeder JS
Drug Metab Dispos; 2006 Apr; 34(4):563-9. PubMed ID: 16415111
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
4. Detection and characterization of the CYP2D6*9x2 gene duplication in two Spanish populations: resolution of AmpliChip CYP450 test no-calls.
Gaedigk A; Hernandez J; García-Solaesa V; Sánchez S; Isidoro-García M
Pharmacogenomics; 2011 Nov; 12(11):1617-22. PubMed ID: 22044417
[TBL] [Abstract][Full Text] [Related]
5. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.
Gaedigk A; Gotschall RR; Forbes NS; Simon SD; Kearns GL; Leeder JS
Pharmacogenetics; 1999 Dec; 9(6):669-82. PubMed ID: 10634130
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients.
González-Tejera G; Gaedigk A; Corey S
P R Health Sci J; 2010 Sep; 29(3):299-304. PubMed ID: 20799519
[TBL] [Abstract][Full Text] [Related]
7. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.
López M; Guerrero J; Jung-Cook H; Alonso ME
Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913
[TBL] [Abstract][Full Text] [Related]
9. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese].
Cai W; Chen B; Tao X; Ling S; Zhang Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
12. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping.
Heller T; Kirchheiner J; Armstrong VW; Luthe H; Tzvetkov M; Brockmöller J; Oellerich M
Ther Drug Monit; 2006 Oct; 28(5):673-7. PubMed ID: 17038884
[TBL] [Abstract][Full Text] [Related]
13. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
[TBL] [Abstract][Full Text] [Related]
14. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
16. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
18. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
[TBL] [Abstract][Full Text] [Related]
19. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos.
Sosa-Macías M; Dorado P; Alanis-Bañuelos RE; Llerena A; Lares-Asseff I
Pharmacology; 2010; 86(1):30-6. PubMed ID: 20588073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
